Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?

被引：3
|
作者：
Thomas, Xavier [1 ]
机构：
[1] Lyon Sud Hosp, Hosp Civils Lyon, Hematol, F-69495 Pierre Benite, France
来源：
LANCET ONCOLOGY | 2015年 / 16卷 / 15期
关键词：
ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; IMATINIB; RESISTANCE; INHIBITOR; PHASE-2;
D O I：
10.1016/S1470-2045(15)00247-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1451 / 1453
页数：4
相关论文
共 50 条
  • [41] Absence of deletions upstream of ABL on the derivative chromosome 9 in patients with Ph-positive ALL.
    Deininger, MWN
    Krahl, R
    Müller, C
    Hennig, E
    Niederwieser, D
    BLOOD, 2000, 96 (11) : 187B - 187B
  • [42] Is the Distribution of Gene Copy Number Alteration in Ph-Positive B-ALL Different From Ph-Negative B-ALL?
    Leons, Gadha K.
    Sharma, Preity
    Gupta, Sanjeev Kumar
    Bakhshi, Sameer
    Gupta, Ritu
    Gajendra, Smeeta
    Roy, Anita
    Sahoo, Ranjit Kumar
    Pushpam, Deepam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S253 - S254
  • [43] Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    Ravandi, Farhad
    Short, Nicholas
    Daver, Naval
    Pemmaraju, Naveen
    Thomas, Deborah
    Yilmaz, Musa
    Kadia, Tapan
    Sasaki, Koji
    Garris, Rebecca
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Konopleva, Marina
    Estrov, Zeev
    Jain, Nitin
    Weirda, William
    Jeanis, Vicky
    Cortes, Jorge
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S257 - S258
  • [44] Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph plus ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
    Jabbour, Elias
    Kantarjian, Hagop M.
    Aldoss, Ibrahim
    Montesinos, Pau
    Leonard, Jessica T.
    Gomez-Almaguer, David
    Baer, Maria R.
    Gambacorti-Passerini, Carlo
    Mccloskey, James
    Minami, Yosuke
    Papayannidis, Cristina
    Rocha, Vanderson
    Rousselot, Philippe
    Vachhani, Pankit
    Wang, Eunice S.
    Yang, Lin
    Hennessy, Meliessa
    Vorog, Alexander
    Patel, Niti
    Yeh, Tammie
    Ribera, Josep-Maria
    BLOOD, 2024, 144 : 2821 - 2823
  • [45] Management of adult Ph-positive acute lymphoblastic leukemia
    Chiaretti, Sabina
    Foa, Robin
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 406 - 413
  • [46] Blinatumomab plus Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience
    Couturier, Marie-Anne
    Thomas, Xavier
    Huguet, Francoise
    Berthon, Celine
    Simand, Celestine
    Hicheri, Yosr
    Hunault, Mathilde
    Chevallier, Patrice
    BLOOD, 2018, 132
  • [47] Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph plus ) ALL.
    Jabbour, Elias
    Martinelli, Giovanni
    Vignetti, Marco
    Ribera, Josep-Maria
    Gomez-Almaguer, David
    Minami, Yosuke
    Xu, Jing
    Srivastava, Shouryadeep
    Neumann, Frank
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Successful autologous stem cell transplantation in Ph-positive ALL patient with refractory invasive pulmonary aspergillosis
    Lisukov, I
    Sizikova, S
    Kulagin, A
    Kruchkova, I
    Gilevich, A
    Klimova, I
    Kozlov, V
    BONE MARROW TRANSPLANTATION, 2004, 34 (06) : 559 - 560
  • [49] Ponatinib for resistant Ph chromosome-positive leukaemia
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2013, 14 (01): : E9 - E9
  • [50] DASATINIB ALONE CAN ALLOW MRD NEGATIVE COLLECTION IN PATIENTS WITH PH-POSITIVE ALL: A CASE REPORT
    Cimminiello, M.
    Pizzuti, M.
    Vertone, D.
    Attolico, I.
    Poggiaspalla, M.
    Magaldi, A.
    Grippo, T.
    Musto, C.
    Olivieri, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 465 - 466
12345